BEAM
Price
$23.44
Change
+$0.04 (+0.17%)
Updated
Jan 17 closing price
Capitalization
1.94B
44 days until earnings call
GLUE
Price
$5.66
Change
-$0.10 (-1.74%)
Updated
Jan 17 closing price
Capitalization
347.42M
53 days until earnings call
Ad is loading...

BEAM vs GLUE

Header iconBEAM vs GLUE Comparison
Open Charts BEAM vs GLUEBanner chart's image
Beam Therapeutics
Price$23.44
Change+$0.04 (+0.17%)
Volume$950.82K
Capitalization1.94B
Monte Rosa Therapeutics
Price$5.66
Change-$0.10 (-1.74%)
Volume$631.11K
Capitalization347.42M
BEAM vs GLUE Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. GLUE commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and GLUE is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (BEAM: $23.44 vs. GLUE: $5.66)
Brand notoriety: BEAM and GLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 80% vs. GLUE: 46%
Market capitalization -- BEAM: $1.94B vs. GLUE: $347.42M
BEAM [@Biotechnology] is valued at $1.94B. GLUE’s [@Biotechnology] market capitalization is $347.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileGLUE’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • GLUE’s FA Score: 0 green, 5 red.
According to our system of comparison, GLUE is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while GLUE’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 3 bearish.
  • GLUE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than GLUE.

Price Growth

BEAM (@Biotechnology) experienced а -11.18% price change this week, while GLUE (@Biotechnology) price change was -0.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

BEAM is expected to report earnings on May 13, 2025.

GLUE is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.94B) has a higher market cap than GLUE($347M). BEAM YTD gains are higher at: -5.484 vs. GLUE (-18.516). GLUE has higher annual earnings (EBITDA): -121.07M vs. BEAM (-160.83M). BEAM has more cash in the bank: 926M vs. GLUE (242M). GLUE has less debt than BEAM: GLUE (43.7M) vs BEAM (162M). BEAM has higher revenues than GLUE: BEAM (350M) vs GLUE (15M).
BEAMGLUEBEAM / GLUE
Capitalization1.94B347M559%
EBITDA-160.83M-121.07M133%
Gain YTD-5.484-18.51630%
P/E RatioN/AN/A-
Revenue350M15M2,333%
Total Cash926M242M383%
Total Debt162M43.7M371%
TECHNICAL ANALYSIS
Technical Analysis
BEAMGLUE
RSI
ODDS (%)
N/A
Bullish Trend 11 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 11 days ago
85%
Momentum
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 11 days ago
90%
MACD
ODDS (%)
Bearish Trend 11 days ago
86%
N/A
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
82%
Bearish Trend 11 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
83%
Bearish Trend 11 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 16 days ago
87%
Declines
ODDS (%)
Bearish Trend 17 days ago
85%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 11 days ago
74%
Bullish Trend 11 days ago
87%
Aroon
ODDS (%)
N/A
Bearish Trend 11 days ago
89%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FZAMX25.400.13
+0.51%
Fidelity Advisor Mid Cap II Z
HHHYX16.880.07
+0.42%
Hartford Schroders Emerging Mkts Eq Y
MNBAX19.530.06
+0.31%
Manning & Napier Pro-Blend Extnd Term S
WCFEX14.640.04
+0.27%
WCM Focused Emerging Mkts Ex Chn Inv
DBICX9.740.01
+0.10%
DWS Global Macro C